Scholar Rock (NASDAQ:SRRK – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

Jay Backstrom; President, Chief Executive Officer, Director; Scholar Rock Holding Corp Tracey Sacco; Chief Commercial Officer; Scholar Rock Holding Corp Good morning and welcome to Scholar Rock's ...

M&T Bank Corp decreased its position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 30.3% during the ...

Scholar Rock (NASDAQ:SRRK) completed enrollment in a Phase 2 trial for its myostatin inhibitor apitegromab. The EMBRAZE study is designed to show its proof-of-concept in preserving lean muscle mass in ...

Sarepta Therapeutics (NASDAQ ... Huntington’s disease candidate advances towards potential FDA approval; Scholar Rock (NASDAQ:SRRK), which has a late-stage spinal muscular atrophy drug and ...

Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Jay Backstrom; President, Chief Executive Officer, Director; Scholar Rock Holding Corp Tracey Sacco; Chief Commercial Officer; Scholar Rock Holding Corp Good morning and welcome to Scholar Rock's ...